The biosimilar wave is no longer approaching. It has arrived. With over 40 biosimilars approved in the United States and more in the pipeline, the transition from reference biologics to their biosimilar alternatives is one of the most consequential formulary management challenges of this decade. The financial opportunity is enormous: reference biologics represent hundreds of billions in annual US drug spending, and biosimilars typically enter the market at 15-40% discounts. But capturing that savings requires navigating a web of rebate contracts, clinical protocols, state substitution laws, physician preferences, and member communication that is far more complex than a standard generic substitution.
Why Biosimilars Are Not Like Generics
Generic drugs are chemically identical to their reference products. A generic atorvastatin tablet has the same active ingredient, in the same strength, in the same dosage form. Pharmacy substitution is automatic in most states, and patients rarely notice the switch.
Biosimilars are different. They are "highly similar" to their reference biologic but not identical, because biologic drugs are large, complex molecules produced by living organisms. The manufacturing process introduces inherent variability. This means:
- Substitution laws vary by state. Only interchangeable biosimilars can be substituted at the pharmacy without a new prescription. Non-interchangeable biosimilars require physician intervention.
- Physician comfort varies widely. Some specialists embrace biosimilars; others are reluctant to switch stable patients. Rheumatologists and oncologists, who prescribe the majority of biologics, have different adoption patterns.
- Rebate dynamics are complex. Reference biologic manufacturers often offer aggressive rebate contracts to maintain market share. The net cost after rebates may make the reference product cheaper than the biosimilar, even though the biosimilar's list price is lower.
The Rebate Trap
The single biggest mistake formulary managers make with biosimilar transitions is looking only at list price. Reference biologic manufacturers respond to biosimilar competition by increasing rebate offers, sometimes dramatically. A rebate contract that guarantees 50% of WAC for the reference product can make it financially advantageous to keep the reference product on formulary, at least in the short term.
The counter-argument, and the one that sophisticated formulary teams are increasingly making, is that long-term reliance on rebates from reference products perpetuates the high list price structure that drives overall drug spending. Biosimilar adoption creates competitive pressure that benefits the entire system over time, even if the immediate financial comparison is close.
The formulary decision should model both scenarios: the rebated cost of the reference product versus the net cost of the biosimilar, projected over a 3-year horizon that accounts for potential rebate erosion as the reference product loses market share. Short-term rebate optimization and long-term cost strategy often point in different directions.
Building a Transition Playbook
Phase 1: Assessment (3-6 months before transition)
- Identify all reference biologics on formulary where biosimilars are available or expected
- Model current utilization: member count, annual spend, prescribing physician distribution
- Analyze rebate contract terms for the reference product and available biosimilar contracts
- Review state substitution laws for each applicable state
- Assess interchangeability status of available biosimilars
Phase 2: Decision and Communication (60-90 days before)
- Present financial model to P&T committee with short-term and long-term projections
- Develop prescriber communication: letters, detail aids, clinical summaries showing biosimilar equivalence data
- Develop member communication: formulary change notices, FAQ documents, call center scripts
- Establish transition supply protocols for members currently on the reference product
Phase 3: Implementation (at transition)
- Update formulary to reflect new preferred status
- Implement prior authorization for reference product (if applicable)
- Configure claims adjudication for step therapy (biosimilar first, reference available via PA)
- Activate member and prescriber communication campaigns
Phase 4: Monitoring (ongoing)
- Track adoption rate: what percentage of new starts are on the biosimilar versus the reference product
- Track switch rate: what percentage of existing members transition
- Monitor clinical outcomes: any increase in adverse events, treatment discontinuation, or ER visits
- Monitor appeals and grievances related to the transition
- Reassess rebate terms quarterly as market share shifts
Technology Requirements
A formulary management system supporting biosimilar transitions needs several capabilities that basic formulary tools lack:
- Biologic/biosimilar relationship mapping. The system must understand which biosimilars reference which biologics, their interchangeability status, and state-specific substitution rules.
- Net cost modeling. Side-by-side comparison of reference product (with current rebate) versus biosimilar (with available rebate), projected across multiple time horizons.
- Physician prescribing analytics. Understanding which prescribers are high-volume biologic prescribers and tracking their biosimilar adoption rates enables targeted outreach.
- Member stickiness modeling. Predicting member behavior in response to the transition (compliance, appeal, plan departure) requires the behavioral modeling we discussed in our previous article on patient stickiness.
The biosimilar opportunity is real, but capturing it requires more analytical sophistication than a typical formulary change. Plans and PBMs that invest in the tools and processes to manage these transitions systematically will realize savings that compound over time as the biosimilar market matures.